Filter News

Anpac Bio-Medical Science Partnering With Asia's Largest Hospital & Other International Medical Institutions For Unprecedented 50,000 Individual Esophageal Cancer Screening

Published: Apr 08, 2016

SACRAMENTO, April 7, 2016 /PRNewswire/ -- Dr. Chris Yu, Chief Executive Officer of international life sciences corporation Anpac Bio-Medical Science Co., Ltd. ("Anpac Bio"), announced today the company is partnering with Asia's largest medical institution, the First Affiliated Hospital of Zhengzhou University (FAHZU), the prestigious Fudan University (FU), and three other respected medical institutions, to launch the largest Esophageal Cancer (EC) investigation to date in the world. Using Anpac Bio's proprietary, "Cancer Differentiation Analysis" (CDA) technology, over 50,000 individuals including those deemed "high risk" -- will be screened, in an effort to identify the disease at its earliest stages.

International life sciences leader Anpac Bio-Medical Science Company has developed breakthrough, proprietary, "Cancer Differentiation Analysis" technology that effectively reinvents cancer screening and early detection. Anpac's proprietary CDA medical devices analyze simple, standard, non-invasive "Blood Biopsies" - resulting in measurably greater early cancer detection sensitivity and specificity, with no harmful side effects in patients. The proven results of 25,000 cases to date demonstrate CDA's research validity achieving an average sensitivity and specificity rate range of 75%-90% for ten different types of cancer -- often identifying the type and location of threatening, diseased cancer cells before they form into tumors.

EC is the eighth-most common cancer globally, with 456,000 new cases annually. However, EC rates vary widely among countries, with about half of all cases occurring in China; greater than 70% of all newly diagnosed EC cases worldwide.

Early EC detection is particularly difficult for clinicians because the cancer does not have an easily discernable "Biomarker"; patients rarely seek treatment until after symptoms persist and the disease has progressed to "late stage" (Stage 3 or 4). Subsequently, the five-year EC survival rate is currently below 20%. But research indicates if EC is caught and treated in its earliest stages, patient five-year survival rate increases exponentially.

Anpac Bio's CDA technology analyzes simple, in vitro, "blood biopsies", using proprietary multi-level, multi-parameter, diagnostic algorithms, to consistently identify EC with remarkably high sensitivity and specificity rates (~ 80%) usually at its earliest stages. Because CDA EC screenings produce no side effects and are more cost-effective and accurate than traditional screenings, FAHZU, FU, and partner institutions deemed CDA well suited to mass screen 50,000 individuals. Upon EC patient identification, the medical institutions will immediately treat the patients, and then continue using CDA to measure progress and five-year survival rates.

"We are very proud to partner with these highly-respected medical institutions in this unprecedented, mass Esophageal Cancer investigation," states Dr. Yu. "By using Anpac Bio's CDA technology, our medical and educational partners can identify Esophageal Cancer patients earlier a major breakthrough in the fight against EC. And if the disease is caught early and treated, the patient has a significantly better survival rate. Many lives will be saved through this 50,000 individual investigation, and we are honored to be a member organization in this effort."

For more information: www.AnpacBio.com.

Logo - http://photos.prnewswire.com/prnh/20151224/318127LOGO

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/anpac-bio-partnering-with-asias-largest-hospital--other-international-medical-institutions-for-unprecedented-50000-individual-esophageal-cancer-screening-300248221.html

SOURCE Anpac Bio-Medical Science Company

Back to news